Your browser is no longer supported. Please, upgrade your browser.
LBPS [NASD]
4D pharma plc
Index- P/E- EPS (ttm)- Insider Own- Shs Outstand22.54M Perf Week12.11%
Market Cap169.03M Forward P/E- EPS next Y-0.46 Insider Trans- Shs Float10.97M Perf Month4.60%
Income- PEG- EPS next Q-0.28 Inst Own0.99% Short Float0.05% Perf Quarter-18.30%
Sales0.69M P/S244.97 EPS this Y- Inst Trans- Short Ratio0.18 Perf Half Y-39.71%
Book/sh- P/B- EPS next Y8.00% ROA- Target Price- Perf Year-
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range6.07 - 15.50 Perf YTD-48.45%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-53.81% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low17.86% ATR0.40
Employees92 Current Ratio- Sales Q/Q16.90% Oper. Margin- RSI (14)48.54 Volatility3.42% 4.06%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.26 Prev Close7.50
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume28.04K Price7.16
Recom1.50 SMA205.04% SMA50-10.22% SMA200-28.88% Volume2,426 Change-4.53%
Oct-12-21 07:00AM  
Sep-15-21 07:00AM  
Sep-09-21 07:00AM  
Aug-02-21 07:00AM  
Jul-29-21 07:00AM  
Jul-26-21 08:00AM  
Jul-06-21 07:00AM  
Jun-29-21 07:00AM  
Jun-22-21 07:00AM  
Jun-04-21 10:14AM  
07:00AM  
May-24-21 09:30AM  
07:00AM  
May-17-21 07:00AM  
Apr-19-21 07:00AM  
Apr-01-21 07:00AM  
4D pharma plc, together with its subsidiaries, engages in the research, development, and production of live biotherapeutic products. The company develops therapeutic candidates, such as MRx0518; MRx-4DP000 for the treatment of asthma and COVID-19; MRx0029 the treatment of central nervous system disorders; Blautix for irritable bowel syndrome; and Thetanix for pediatric crohn's disease. It also develops products candidates, including MRx1299 for solid tumors, MRx0005 for neurodegeneration, MRx0006 for rheumatoid arthritis, and MRx0002 for multiple sclerosis. The company develops MicroRx platform to discover new LBP candidates for major diseases. 4D pharma plc has a collaboration agreement with Merck & Co., Inc. to conduct a clinical trial evaluating the combination of Keytruda and MRx0518 in patients with solid tumors. The company was formerly known as Schosween 18 Limited. 4D pharma plc was incorporated in 2014 and is headquartered in Leeds, the United Kingdom.